The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Patient preferences at the time of relapse in multiple myeloma
Lisa Leypoldt, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses Patient preferences at the time of relapse in multiple myeloma. Dr Leypoldt emphasizes that for both patients and caregivers, treatment efficacy is the most important aspect of treatment, but also highlights the need to consider individual patient values and priorities. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
For patients, actually both patients and also caregivers, the most important aspect is treatment efficacy. This was also confirmed by a large survey, which I was able to present earlier today, that this is really the main treatment goal, efficacy. But then if you can look a little further than just efficacy, because today we are lucky that we do have many efficacious options in relapse available, then there are some discrepancies because patients, they put a higher importance also to aspects such as minimizing side effects and quality of life and also convenience of treatment than do their caregivers...
For patients, actually both patients and also caregivers, the most important aspect is treatment efficacy. This was also confirmed by a large survey, which I was able to present earlier today, that this is really the main treatment goal, efficacy. But then if you can look a little further than just efficacy, because today we are lucky that we do have many efficacious options in relapse available, then there are some discrepancies because patients, they put a higher importance also to aspects such as minimizing side effects and quality of life and also convenience of treatment than do their caregivers. So I think this is really important to have in mind when you go into the conversation with your patient about the next treatment option that you really get a better impression of what is important to them, how they live their life and then really taking all this into account, come to really shared decision-making but how this process of shared decision-making looks like that will be individual as each one of us is individual as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory role/honoraria: GSK, Sanofi, Janssen, Bristol Myers Squibb/Celgene; Research support: AbbVie, GSK (both to the institution); Travel support: Sanofi; Other (travel support, training): GSK, Sanofi, AbbVie.
